News Articles | Pfizer Singapore

Biopharma Leaders Unite To Stand With Science

Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19

PFIZER INVESTS $120MIL IN BIOTECH INNOVATION

Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027

AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE

RECENT PRESS RELEASES

05/05/2021 - PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

28/04/2021 - Pfizer Acquires Amplyx Pharmaceuticals

22/04/2021 - Pfizer Declares Second-Quarter 2021 Dividend

08/03/2021 - Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

04/03/2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

03/03/2021 - U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer

26/02/2021 - European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

26/02/2021 - EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

25/02/2021 - Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

23/02/2021 - U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)

22/02/2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

19/02/2021 - Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

17/02/2021 - Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

17/02/2021 - Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women

17/02/2021 - Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma